LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)

Autor:	P. Neven, P.A. Fasching, S. Chia, G. Jerusalem, M. De Laurentiis, S.-A. Im, K. Petrakova, G.V. Bianchi, M. Martin Jimenez, A. Nusch, G.S. Sonke, L. de la Cruz Merino, J.T. Beck, J.P. Zarate, Y. Wang, A. Chakravartty, C. Wang, D. Slamon
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S194
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8782131bc8ee7cfe6cb6c0f3f4269dd9 https://doi.org/10.1016/j.annonc.2022.03.280 Zobrazit plný text záznamu